Home / Author Archives: bio972

Author Archives: bio972

MediWound to Ring the NASDAQ Stock Market Closing Bell in Recognition of Burn Awareness Week מדיוונד יצלצל פעמון הסגירה בבורסת הנאסד"ק כחלק משבוע של מודעות לצריבה

MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced that Gal Cohen, MediWound’s Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell today (February 5, 2015) in ...

Read More »

Evogene Incorporates Gene Optimization Program into Collaboration with Monsanto אבוג'ן משלב תכנית לאופטימיזציה גנטית בתוך שיתוף הפעולה שלו עם מונסנטו

Evogene is incorporating its new gene optimization program into its long-term collaboration with Monsanto. The addition comes after Evogene identified and validated more than 1,000 genes that have entered Monsanto’s product pipeline which improve yield and stress tolerance. Evogene’s computational technology system has the potential to ...

Read More »

Alcobra Ltd. Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Over-Allotment Option אלקוברה בע״מ מכריז על סגירת הנפקה של מניות רגילות

After its stock dropped over 80% last year with failed Phase III trial results, Alcobra has raised approximately $27.9 million in a public offering of ordinary shares. The full over allotment option was exercised by the underwriters: 975,000 of the 7.5 million ...

Read More »

Therapix Biosciences and Dekel Pharmaceuticals Sign Binding Term Sheet Outlining Licensing and Royalty Agreement תראפיקס ביוסיינסס בע"מ ודקל פארמסוטיקלס בע"מ חתמו על הסכם לרישוי ותמלוגים

Therapix Biosciences, a biopharma company focused on cannabinoid drugs, has signed a binding term sheet with Dekel Pharmaceuticals for the exclusive worldwide right to develop, manufacture and commercialize combination drug therapies based on Dekel’s technology. The technology is based on the “entourage effect” ...

Read More »

cCAM Biotherapeutics Receives FDA Approval to Initiate Phase 1 Trial for CM-24, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy סיקאם ביות'רפיוטיקס בע"מ קיבל את האישור ליזום ניסוי קליני לסרטן

First-in-human Phase 1 trial expected to commence in Q1 2015 MISGAV, Israel–(BUSINESS WIRE)–cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that it has received approval form the US Food and Drug ...

Read More »

Pluristem Granted Patent for Foundational Cell Harvesting Technology in South Africa פלוריסטם קיבל פטנט בדרום אפריקה לטכנולוגיה לקציר תאים

Patent Covers Methods for Using Vibration to Harvest Large Yields of Viable Cells Grown With Three-Dimensional Technology HAIFA, Israel, Jan. 6, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that ...

Read More »